Key facts
- This page summarizes Debra Yu's Form 4 filing for LianBio (LIANY).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 May 2022, 16:15.
Debra Yu - 04 May 2022 Form 4 Insider Report for LianBio (LIANY)
- Reporting relationship
- President & Chief Strategy Officer
- Issuer ticker
- LIANY
- Reported as of
- 04 May 2022
- Net transaction value
- +$1,710,000
- SEC form
- 4
- Accepted by SEC
- 06 May 2022, 16:15:15 UTC
- Prior SEC filing
- 27 Apr 2022
- Next SEC filing
- 12 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Angela Chen, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Debra Yu filed Form 4 for LianBio (LIANY) on 06 May 2022.
Change
- Previous filing in this sequence was filed on 27 Apr 2022.
- Current net transaction value: +$1,710,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LIAN
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $1,710,000
- Shares
- +1,000,000
- Change %
- Price
- $1.71
- Shares after
- 1,000,000
- Date
- 04 May 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LIAN
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,000,000
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 999,947
- Date
- 04 May 2022
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,000,000
- Exercise price
- $1.71
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
1/3 of the shares underlying the option vested and became exercisable on January 1, 2020; 1/3 of the shares underlying the option vested and became exercisable on October 1, 2020 and 1/3 of the shares underlying the option vested and became exercisable on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date.
SEC remarks
President & Chief Strategy Officer